PETS earnings analysis
What we found in PETS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PetMed Express reported $41.015 million of revenue and $(0.28) of EPS; revenue declined 19.9% year over year and EPS missed the provided $0.12 estimate. The GAAP net loss improved to $6.145 million from $34.152 million, but gross margin fell to 23.3%, adjusted EBITDA was negative $3.448 million, and free cash flow was negative $9 million. Liquidity is constrained by $13.1 million of cash, while four previously disclosed material weaknesses remain unremediated. No quantitative guidance or material risk-factor changes were provided.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue beat estimates but declined year over year
- Revenue was $41.015 million, down 19.9% from the prior-year period, although it exceeded the provided $10.336 million estimate.
- GAAP loss narrowed materially
- GAAP net loss narrowed to $6.145 million from $34.152 million, primarily because the prior-year period included a $27.258 million impairment charge.
- Gross margin contracted sharply
- Gross margin was 23.3%, down from 37.5% in the prior listed period, a 14.2 percentage-point contraction.
- Free cash flow remained negative
- Free cash flow was negative $9 million, following negative $5 million in the prior listed period, indicating continued cash consumption.
- Debt-free balance sheet
- The company reported $13.1 million of cash and cash equivalents and no debt obligations as of June 30, 2026.
- SAP ERP implementation progressed
- Management continued implementing SAP ERP modules during the quarter, modifying financial reporting processes and related controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Underlying profitability remains negative
- Adjusted EBITDA deteriorated to negative $3.448 million despite the narrower $6.145 million GAAP net loss, signaling continued operating pressure.
- Cash burn threatens liquidity
- Cash and cash equivalents were $13.1 million at June 30, 2026, while free cash flow was negative $9 million, creating a material liquidity risk despite the absence of debt.
- Material control weaknesses persist
- Four material weaknesses—sales taxes, information technology general controls, revenue recognition, and cooperative advertising and vendor reimbursements—had not been fully remediated as of June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.28
- Gross margin
- 23.3%
- Operating margin
- -25.8%
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance; no forward outlook was disclosed in the supplied MD&A/extract.
The filing reads worse than the one before it.
What came before.
- 10-K · June 2, 2026
- PetMed Express, Inc. experienced a significant 21.1% decline in revenue in FY 2026, resulting in a net loss of $57.3 million, compared to a loss of $6.3 million the previous fiscal year. Factors behind the downturn…
- 10-K · October 14, 2025
- The 10-K discloses a strategic shift from a digital-only model to an omnichannel roadmap (Amazon entry, private label and retail licensing) while flagging a material restatement and control failures. Business metrics…
- 10-Q · November 7, 2024
- PetMed Express reported quarterly revenue of $59.57M, down 16.1% YoY (from $70.999M), but delivered GAAP diluted EPS of $0.11 versus $0.03 a year ago. Gross margin improved to 29.1% (from 28.3%), while operating margin…
- 10-K · June 14, 2024
- PetMed Express positions itself as a digital-first pet wellness company after the April 2023 acquisition of PetCareRx, aiming to consolidate brands, expand product assortment beyond prescriptions, and invest in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PETS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever